MEDINDIA
English
हिन्दी
Español
français
中文
Email
4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lidocaine.
Abiraterone
The serum concentration of Lidocaine can be increased when it is combined with Abiraterone.
Acebutolol
The serum concentration of Lidocaine can be increased when it is combined with Acebutolol.
Acenocoumarol
The metabolism of Acenocoumarol can be decreased when combined with Lidocaine.
Acepromazine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Aceprometazine.
Acetaminophen
The metabolism of Acetaminophen can be decreased when combined with Lidocaine.
Acetyl Sulfisoxazole
The metabolism of Lidocaine can be decreased when combined with Acetyl sulfisoxazole.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Lidocaine.
Albendazole
The metabolism of Albendazole can be decreased when combined with Lidocaine.
Alfaxalone
The risk or severity of adverse effects can be increased when Lidocaine is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Lidocaine.
Almotriptan
The metabolism of Almotriptan can be decreased when combined with Lidocaine.
Alosetron
The metabolism of Alosetron can be decreased when combined with Lidocaine.
Alphaprodine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Alphaprodine.
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Lidocaine.
Alprenolol
The serum concentration of Lidocaine can be increased when it is combined with Alprenolol.
Aminophylline
The metabolism of Aminophylline can be decreased when combined with Lidocaine.
Aminopyrine
The metabolism of Aminophenazone can be decreased when combined with Lidocaine.
Amiodarone
The risk or severity of generalized seizure and bradycardia can be increased when Amiodarone is combined with Lidocaine.
Amisulpride
The risk or severity of adverse effects can be increased when Lidocaine is combined with Amisulpride.
Amitriptyline
The metabolism of Amitriptyline can be decreased when combined with Lidocaine.
Amobarbital
The risk or severity of adverse effects can be increased when Amobarbital is combined with Lidocaine.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Lidocaine.
Anagrelide
The metabolism of Anagrelide can be decreased when combined with Lidocaine.
Antipyrine
The metabolism of Antipyrine can be decreased when combined with Lidocaine.
Apalutamide
The serum concentration of Lidocaine can be decreased when it is combined with Apalutamide.
Apixaban
The metabolism of Apixaban can be decreased when combined with Lidocaine.
Aprepitant
The serum concentration of Lidocaine can be increased when it is combined with Aprepitant.
Aripiprazole
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lidocaine.
Artemether
The metabolism of Lidocaine can be decreased when combined with Artemether.
Articaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Articaine.
Asenapine
The serum concentration of Lidocaine can be increased when it is combined with Asenapine.
Asunaprevir
The serum concentration of Asunaprevir can be increased when it is combined with Lidocaine.
Atazanavir
The metabolism of Lidocaine can be decreased when combined with Atazanavir.
Atenolol
The serum concentration of Lidocaine can be increased when it is combined with Atenolol.
Atomoxetine
The metabolism of Lidocaine can be decreased when combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Lidocaine is combined with Atorvastatin.
Axitinib
The metabolism of Axitinib can be decreased when combined with Lidocaine.
Azelastine
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Azithromycin
The metabolism of Lidocaine can be decreased when combined with Azithromycin.
Baclofen
The risk or severity of adverse effects can be increased when Baclofen is combined with Lidocaine.
Barbital
The risk or severity of adverse effects can be increased when Lidocaine is combined with Barbital.
Bendamustine
The metabolism of Bendamustine can be decreased when combined with Lidocaine.
Benoxinate
The risk or severity of adverse effects can be increased when Lidocaine is combined with Oxybuprocaine.
Benperidol
The risk or severity of adverse effects can be increased when Lidocaine is combined with Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Benzocaine.
Benzyl Alcohol
The metabolism of Benzyl alcohol can be decreased when combined with Lidocaine.
Betaxolol
The serum concentration of Lidocaine can be increased when it is combined with Betaxolol.
Bisoprolol
The serum concentration of Lidocaine can be increased when it is combined with Bisoprolol.
Boceprevir
The metabolism of Lidocaine can be decreased when combined with Boceprevir.
Bopindolol
The serum concentration of Lidocaine can be increased when it is combined with Bopindolol.
Bortezomib
The metabolism of Lidocaine can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Lidocaine can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Lidocaine can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Lidocaine.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Lidocaine.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Lidocaine.
Brexpiprazole
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Lidocaine.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
Bromazepam
The metabolism of Bromazepam can be decreased when combined with Lidocaine.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lidocaine.
Bromperidol
The risk or severity of adverse effects can be increased when Lidocaine is combined with Bromperidol.
Brompheniramine
The risk or severity of adverse effects can be increased when Brompheniramine is combined with Lidocaine.
Brotizolam
The risk or severity of adverse effects can be increased when Lidocaine is combined with Brotizolam.
Bupivacaine
The metabolism of Bupivacaine can be decreased when combined with Lidocaine.
Bupranolol
The serum concentration of Lidocaine can be increased when it is combined with Bupranolol.
Buprenorphine
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion
The metabolism of Lidocaine can be decreased when combined with Bupropion.
Buspirone
The risk or severity of adverse effects can be increased when Buspirone is combined with Lidocaine.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Lidocaine.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Lidocaine.
Butamben
The risk or severity of adverse effects can be increased when Lidocaine is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Lidocaine is combined with Butethal.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Lidocaine.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Lidocaine.
Caffeine
The metabolism of Lidocaine can be decreased when combined with Caffeine.
Capecitabine
The metabolism of Lidocaine can be decreased when combined with Capecitabine.
Carbamazepine
The metabolism of Lidocaine can be increased when combined with Carbamazepine.
Carbinoxamine
The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Lidocaine.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Lidocaine.
Carmustine
The metabolism of Carmustine can be decreased when combined with Lidocaine.
Carteolol
The serum concentration of Lidocaine can be increased when it is combined with Carteolol.
Carvedilol
The serum concentration of Lidocaine can be increased when it is combined with Carvedilol.
Celecoxib
The metabolism of Lidocaine can be decreased when combined with Celecoxib.
Celiprolol
The serum concentration of Lidocaine can be increased when it is combined with Celiprolol.
Ceritinib
The serum concentration of Lidocaine can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Lidocaine.
Cetirizine
The risk or severity of adverse effects can be increased when Cetirizine is combined with Lidocaine.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Lidocaine is combined with Chloral hydrate.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lidocaine.
Chlormethiazole
The risk or severity of adverse effects can be increased when Lidocaine is combined with clomethiazole.
Chlormezanone
The risk or severity of adverse effects can be increased when Lidocaine is combined with Chlormezanone.
Chloroprocaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Chloroprocaine.
Chloroquine
The metabolism of Lidocaine can be decreased when combined with Chloroquine.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lidocaine.
CHLORPHENIRAMINE POLISTIREX
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lidocaine.
Chlorpromazine
The metabolism of Chlorpromazine can be decreased when combined with Lidocaine.
Chlorprothixene
The risk or severity of adverse effects can be increased when Lidocaine is combined with Chlorprothixene.
Chlorzoxazone
The metabolism of Chlorzoxazone can be decreased when combined with Lidocaine.
Cholecalciferol
The metabolism of Lidocaine can be decreased when combined with Cholecalciferol.
Cilostazol
The metabolism of Cilostazol can be decreased when combined with Lidocaine.
Cimetidine
The metabolism of Lidocaine can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Lidocaine can be decreased when combined with Cinacalcet.
Cinnarizine
The metabolism of Cinnarizine can be decreased when combined with Lidocaine.
Cisapride
The metabolism of Cisapride can be decreased when combined with Lidocaine.
Citalopram
The metabolism of Lidocaine can be decreased when combined with Citalopram.
Clarithromycin
The metabolism of Lidocaine can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Lidocaine can be decreased when combined with Clemastine.
Clenbuterol
The metabolism of Clenbuterol can be decreased when combined with Lidocaine.
Clevidipine
The metabolism of Clevidipine can be decreased when combined with Lidocaine.
Clevidipine butyrate
The metabolism of Clevidipine can be decreased when combined with Lidocaine.
Clidinium
The risk or severity of adverse effects can be increased when Clidinium is combined with Lidocaine.
Clidinium bromide
The risk or severity of adverse effects can be increased when Clidinium is combined with Lidocaine.
Clobazam
The metabolism of Lidocaine can be decreased when combined with Clobazam.
Clofezone
The metabolism of Lidocaine can be decreased when combined with Rabeprazole.
Clomipramine
The metabolism of Clomipramine can be decreased when combined with Lidocaine.
Clonazepam
The risk or severity of adverse effects can be increased when Clonazepam is combined with Lidocaine.
Clonidine
The metabolism of Clonidine can be decreased when combined with Lidocaine.
Clopidogrel
The metabolism of Clopidogrel can be decreased when combined with Lidocaine.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Lidocaine.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Lidocaine.
Clotrimazole
The metabolism of Lidocaine can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Clozapine can be decreased when combined with Lidocaine.
Cobicistat
The serum concentration of Lidocaine can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Lidocaine can be decreased when combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Lidocaine.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Lidocaine.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Lidocaine.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Lidocaine.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Lidocaine.
Crisaborole
The metabolism of Lidocaine can be decreased when combined with Crisaborole.
Crizotinib
The metabolism of Lidocaine can be decreased when combined with Crizotinib.
Curcumin
The metabolism of Lidocaine can be decreased when combined with Curcumin.
Cyclizine
The risk or severity of adverse effects can be increased when Cyclizine is combined with Lidocaine.
Cyclobenzaprine
The metabolism of Cyclobenzaprine can be decreased when combined with Lidocaine.
Cyclosporine
The metabolism of Lidocaine can be decreased when combined with Cyclosporine.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Lidocaine.
Cyproterone Acetate
The serum concentration of Lidocaine can be decreased when it is combined with Cyproterone acetate.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lidocaine.
Dabrafenib
The serum concentration of Lidocaine can be decreased when it is combined with Dabrafenib.
Dacarbazine
The metabolism of Dacarbazine can be decreased when combined with Lidocaine.
Dantrolene
The risk or severity of adverse effects can be increased when Dantrolene is combined with Lidocaine.
Dapagliflozin
The metabolism of Dapagliflozin can be decreased when combined with Lidocaine.
Dapiprazole
The risk or severity of adverse effects can be increased when Lidocaine is combined with Dapiprazole.
Dapsone
The risk or severity of adverse effects can be increased when Dapsone is combined with Lidocaine.
Darifenacin
The metabolism of Lidocaine can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Lidocaine can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Lidocaine can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Lidocaine can be increased when it is combined with Dasatinib.
Daunorubicin
The metabolism of Daunorubicin can be decreased when combined with Lidocaine.
Deferasirox
The serum concentration of Lidocaine can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Lidocaine can be decreased when combined with Delavirdine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Lidocaine.
Desipramine
The serum concentration of Lidocaine can be increased when it is combined with Desipramine.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Lidocaine.
Desvenlafaxine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Desvenlafaxine.
Deutetrabenazine
The metabolism of Deutetrabenazine can be decreased when combined with Lidocaine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lidocaine.
Dexfenfluramine
The metabolism of Dexfenfluramine can be decreased when combined with Lidocaine.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Dexmedetomidine.
Dextromoramide
The risk or severity of adverse effects can be increased when Lidocaine is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Dezocine.
Diazepam
The metabolism of Diazepam can be decreased when combined with Lidocaine.
Dibucaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Cinchocaine.
Diclofenac
The metabolism of Diclofenac can be decreased when combined with Lidocaine.
Difenoxin
The risk or severity of adverse effects can be increased when Difenoxin is combined with Lidocaine.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lidocaine.
Dihydroergocornine
The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lidocaine.
Dihydroergocristine
The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lidocaine.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lidocaine.
Diltiazem
The metabolism of Lidocaine can be decreased when combined with Diltiazem.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lidocaine.
Dinoprostone
The metabolism of Dinoprostone can be decreased when combined with Lidocaine.
Diphenhydramine
The metabolism of Diphenhydramine can be decreased when combined with Lidocaine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lidocaine.
Disopyramide
Disopyramide may increase the arrhythmogenic activities of Lidocaine.
Dofetilide
Lidocaine may increase the arrhythmogenic activities of Dofetilide.
Domperidone
The metabolism of Domperidone can be decreased when combined with Lidocaine.
Dothiepin
The metabolism of Lidocaine can be decreased when combined with Dosulepin.
Doxepin
The metabolism of Doxepin can be decreased when combined with Lidocaine.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Lidocaine.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Lidocaine.
Doxycycline
The metabolism of Lidocaine can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Lidocaine can be decreased when combined with Doxycycline.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
Dronedarone
Lidocaine may increase the arrhythmogenic activities of Dronedarone.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
Duloxetine
The metabolism of Duloxetine can be decreased when combined with Lidocaine.
Dyclonine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Dyclonine.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Lidocaine.
Efavirenz
The metabolism of Lidocaine can be decreased when combined with Efavirenz.
Eliglustat
The metabolism of Lidocaine can be decreased when combined with Eliglustat.
Eltrombopag
The metabolism of Eltrombopag can be decreased when combined with Lidocaine.
Enasidenib
The metabolism of Enasidenib can be decreased when combined with Lidocaine.
Enflurane
The risk or severity of adverse effects can be increased when Enflurane is combined with Lidocaine.
Entacapone
The risk or severity of adverse effects can be increased when Entacapone is combined with Lidocaine.
Enzalutamide
The serum concentration of Lidocaine can be decreased when it is combined with Enzalutamide.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Lidocaine.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Lidocaine.
Erlotinib
The metabolism of Erlotinib can be decreased when combined with Lidocaine.
Erythromycin
The metabolism of Lidocaine can be decreased when combined with Erythromycin.
Escitalopram
The risk or severity of adverse effects can be increased when Lidocaine is combined with Escitalopram.
Esmolol
The serum concentration of Lidocaine can be increased when it is combined with Esmolol.
Estazolam
The risk or severity of adverse effects can be increased when Estazolam is combined with Lidocaine.
Estradiol
The metabolism of Estradiol can be decreased when combined with Lidocaine.
Estradiol 3-Benzoate
The metabolism of Estradiol benzoate can be decreased when combined with Lidocaine.
Estradiol acetate
The metabolism of Estradiol acetate can be decreased when combined with Lidocaine.
Estradiol Cypionate
The metabolism of Estradiol cypionate can be decreased when combined with Lidocaine.
Estradiol Valerate
The metabolism of Estradiol valerate can be decreased when combined with Lidocaine.
Estrogens, Conjugated (USP)
The metabolism of Conjugated estrogens can be decreased when combined with Lidocaine.
Estrone
The metabolism of Estrone can be decreased when combined with Lidocaine.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Lidocaine.
Ethanol
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lidocaine.
Ethosuximide
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lidocaine.
Ethotoin
The risk or severity of adverse effects can be increased when Ethotoin is combined with Lidocaine.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl loflazepate.
Ethylmorphine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Ethylmorphine.
Etidocaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Etifoxine.
Etomidate
The risk or severity of adverse effects can be increased when Lidocaine is combined with Etomidate.
Etoposide
The metabolism of Etoposide can be decreased when combined with Lidocaine.
Etoricoxib
The metabolism of Etoricoxib can be decreased when combined with Lidocaine.
Etravirine
The serum concentration of Lidocaine can be decreased when it is combined with Etravirine.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Lidocaine.
Ezogabine
The risk or severity of adverse effects can be increased when Ezogabine is combined with Lidocaine.
Felbamate
The risk or severity of adverse effects can be increased when Felbamate is combined with Lidocaine.
Felodipine
The metabolism of Lidocaine can be decreased when combined with Felodipine.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Lidocaine.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lidocaine.
Fexofenadine
The risk or severity of adverse effects can be increased when Fexofenadine is combined with Lidocaine.
Flibanserin
The risk or severity of adverse effects can be increased when Flibanserin is combined with Lidocaine.
Floxuridine
The metabolism of Lidocaine can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Lidocaine can be decreased when combined with Fluconazole.
Flunarizine
The metabolism of Flunarizine can be decreased when combined with Lidocaine.
Flunitrazepam
The metabolism of Flunitrazepam can be decreased when combined with Lidocaine.
Fluorouracil
The metabolism of Lidocaine can be decreased when combined with Fluorouracil.
Fluoxetine
The metabolism of Lidocaine can be decreased when combined with Fluoxetine.
Flupenthixol
The risk or severity of adverse effects can be increased when Flupentixol is combined with Lidocaine.
Fluphenazine
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Lidocaine.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Lidocaine.
Fluspirilene
The risk or severity of adverse effects can be increased when Lidocaine is combined with Fluspirilene.
Flutamide
The metabolism of Flutamide can be decreased when combined with Lidocaine.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Lidocaine.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Lidocaine.
Fluvoxamine
The metabolism of Lidocaine can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Lidocaine can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Lidocaine can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Lidocaine can be increased when combined with Fosphenytoin.
Fospropofol
The risk or severity of adverse effects can be increased when Lidocaine is combined with Fospropofol.
Frovatriptan
The metabolism of Frovatriptan can be decreased when combined with Lidocaine.
Fusidate
The serum concentration of Lidocaine can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Lidocaine can be increased when it is combined with Fusidic Acid.
Gabapentin
The risk or severity of adverse effects can be increased when Gabapentin is combined with Lidocaine.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Lidocaine.
Gemfibrozil
The metabolism of Lidocaine can be decreased when combined with Gemfibrozil.
Genistein
The metabolism of Genistein can be decreased when combined with Lidocaine.
Glutethimide
The risk or severity of adverse effects can be increased when Lidocaine is combined with Glutethimide.
Grepafloxacin
The metabolism of Grepafloxacin can be decreased when combined with Lidocaine.
Guanabenz
The metabolism of Guanabenz can be decreased when combined with Lidocaine.
Guanfacine
The risk or severity of adverse effects can be increased when Guanfacine is combined with Lidocaine.
Halazepam
The risk or severity of adverse effects can be increased when Lidocaine is combined with Halazepam.
Haloperidol
The metabolism of Haloperidol can be decreased when combined with Lidocaine.
Halothane
The risk or severity of adverse effects can be increased when Lidocaine is combined with Halothane.
Heroin
The risk or severity of adverse effects can be increased when Lidocaine is combined with Heroin.
Hesperetin
The metabolism of Hesperetin can be decreased when combined with Lidocaine.
Hexobarbital
The metabolism of Hexobarbital can be decreased when combined with Lidocaine.
Hyaluronidase
The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Lidocaine.
Hyaluronidase, Ovine
The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Lidocaine.
Hydrocodone
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lidocaine.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
Hypoxis hemerocallidea root extract
The serum concentration of Lidocaine can be decreased when it is combined with St. John's Wort.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Lidocaine.
Ibutilide
Lidocaine may increase the arrhythmogenic activities of Ibutilide.
Idelalisib
The metabolism of Lidocaine can be decreased when combined with Idelalisib.
Iloperidone
The metabolism of Iloperidone can be decreased when combined with Lidocaine.
Imatinib
The metabolism of Lidocaine can be decreased when combined with Imatinib.
Imipramine
The metabolism of Imipramine can be decreased when combined with Lidocaine.
Imiquimod
The metabolism of Imiquimod can be decreased when combined with Lidocaine.
Indinavir
The metabolism of Lidocaine can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Lidocaine can be decreased when combined with Indinavir.
Irbesartan
The metabolism of Lidocaine can be decreased when combined with Irbesartan.
Isavuconazole
The serum concentration of Lidocaine can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Lidocaine can be decreased when combined with Isavuconazonium.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Lidocaine.
Isoniazid
The metabolism of Lidocaine can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Lidocaine can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Lidocaine can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Lidocaine can be increased when it is combined with Ivacaftor.
Ixazomib
The metabolism of Ixazomib can be decreased when combined with Lidocaine.
Ketamine
The risk or severity of adverse effects can be increased when Ketamine is combined with Lidocaine.
Ketazolam
The risk or severity of adverse effects can be increased when Lidocaine is combined with Ketazolam.
Ketoconazole
The metabolism of Lidocaine can be decreased when combined with Ketoconazole.
Labetalol
The serum concentration of Lidocaine can be increased when it is combined with Labetalol.
Lamotrigine
The risk or severity of adverse effects can be increased when Lamotrigine is combined with Lidocaine.
Lapatinib
The metabolism of Lidocaine can be decreased when combined with Lapatinib.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Lidocaine.
Leflunomide
The metabolism of Leflunomide can be decreased when combined with Lidocaine.
Levetiracetam
The risk or severity of adverse effects can be increased when Levetiracetam is combined with Lidocaine.
Levobetaxolol
The serum concentration of Lidocaine can be increased when it is combined with Levobetaxolol.
Levobunolol
The serum concentration of Lidocaine can be increased when it is combined with Levobunolol.
Levobupivacaine
The metabolism of Levobupivacaine can be decreased when combined with Lidocaine.
Levocabastine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Levocetirizine is combined with Lidocaine.
Levodopa
The risk or severity of adverse effects can be increased when Levodopa is combined with Lidocaine.
Levomethadyl
The risk or severity of adverse effects can be increased when Lidocaine is combined with Levomethadyl Acetate.
Levomilnacipran
The risk or severity of adverse effects can be increased when Lidocaine is combined with Levomilnacipran.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Lidocaine.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Lidocaine.
Lithium
The risk or severity of adverse effects can be increased when Lidocaine is combined with Lithium.
Lithium Cation
The risk or severity of adverse effects can be increased when Lidocaine is combined with Lithium.
Lofexidine
The therapeutic efficacy of Lidocaine can be increased when used in combination with Lofexidine.
Lomefloxacin
The metabolism of Lomefloxacin can be decreased when combined with Lidocaine.
Lopinavir
The metabolism of Lidocaine can be decreased when combined with Lopinavir.
Loratadine
The risk or severity of adverse effects can be increased when Loratadine is combined with Lidocaine.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lidocaine.
Lorcaserin
The metabolism of Lorcaserin can be decreased when combined with Lidocaine.
Lormetazepam
The risk or severity of adverse effects can be increased when Lidocaine is combined with Lormetazepam.
Losartan
The metabolism of Lidocaine can be decreased when combined with Losartan.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Lidocaine.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Lidocaine.
Luliconazole
The serum concentration of Lidocaine can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Lidocaine can be increased when it is combined with Lumacaftor.
Lumefantrine
The metabolism of Lidocaine can be decreased when combined with Lumefantrine.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Lidocaine.
Magnesium Sulfate
The therapeutic efficacy of Lidocaine can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Lidocaine can be increased when used in combination with Magnesium sulfate.
Malathion
The metabolism of Malathion can be decreased when combined with Lidocaine.
Manidipine
The metabolism of Lidocaine can be decreased when combined with Manidipine.
Maprotiline
The metabolism of Maprotiline can be decreased when combined with Lidocaine.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Lidocaine.
Melatonin
The metabolism of Melatonin can be decreased when combined with Lidocaine.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Lidocaine.
Mephenytoin
The metabolism of Mephenytoin can be decreased when combined with Lidocaine.
Mephobarbital
The risk or severity of adverse effects can be increased when Lidocaine is combined with Methylphenobarbital.
Mepindolol
The serum concentration of Lidocaine can be increased when it is combined with Mepindolol.
Mepivacaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Mepivacaine.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Lidocaine.
Mesoridazine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Mesoridazine.
Metaxalone
The risk or severity of adverse effects can be increased when Metaxalone is combined with Lidocaine.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Lidocaine.
Methadone
The metabolism of Methadone can be decreased when combined with Lidocaine.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Lidocaine is combined with Methadyl Acetate.
Methapyrilene
The risk or severity of adverse effects can be increased when Lidocaine is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Lidocaine is combined with Methaqualone.
Methocarbamol
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Lidocaine.
Methohexital
The risk or severity of adverse effects can be increased when Methohexital is combined with Lidocaine.
Methotrimeprazine
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxyflurane
The metabolism of Methoxyflurane can be decreased when combined with Lidocaine.
Methsuximide
The risk or severity of adverse effects can be increased when Methsuximide is combined with Lidocaine.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lidocaine.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Lidocaine.
Metipranolol
The serum concentration of Lidocaine can be increased when it is combined with Metipranolol.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Lidocaine.
Metylperon
The risk or severity of adverse effects can be increased when Lidocaine is combined with Melperone.
Metyrosine
Lidocaine may increase the sedative activities of Metyrosine.
Mexiletine
The metabolism of Lidocaine can be decreased when combined with Mexiletine.
Mianserin
The metabolism of Mianserin can be decreased when combined with Lidocaine.
Midazolam
The risk or severity of adverse effects can be increased when Midazolam is combined with Lidocaine.
Midostaurin
The metabolism of Lidocaine can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Lidocaine can be increased when it is combined with Mifepristone.
Milnacipran
The risk or severity of adverse effects can be increased when Lidocaine is combined with Milnacipran.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
Mirabegron
The metabolism of Lidocaine can be decreased when combined with Mirabegron.
Mirtazapine
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Mitotane
The serum concentration of Lidocaine can be decreased when it is combined with Mitotane.
Molindone
The risk or severity of adverse effects can be increased when Lidocaine is combined with Molindone.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Lidocaine.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
Nabumetone
The metabolism of Nabumetone can be decreased when combined with Lidocaine.
Nadolol
The serum concentration of Lidocaine can be increased when it is combined with Nadolol.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Lidocaine.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Lidocaine.
Naproxen
The metabolism of Naproxen can be decreased when combined with Lidocaine.
Nebivolol
The serum concentration of Lidocaine can be increased when it is combined with Nebivolol.
Nefazodone
The metabolism of Lidocaine can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Lidocaine can be decreased when combined with Nelfinavir.
Netupitant
The serum concentration of Lidocaine can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Lidocaine can be increased when combined with Nevirapine.
Nicardipine
The metabolism of Lidocaine can be decreased when combined with Nicardipine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Lidocaine.
Nicotine
The metabolism of Nicotine can be decreased when combined with Lidocaine.
Nicotine Polacrilex
The metabolism of Nicotine can be decreased when combined with Lidocaine.
Nifedipine
The metabolism of Nifedipine can be decreased when combined with Lidocaine.
Nilotinib
The metabolism of Lidocaine can be decreased when combined with Nilotinib.
Nintedanib
The serum concentration of Nintedanib can be increased when it is combined with Lidocaine.
Nitrazepam
The risk or severity of adverse effects can be increased when Nitrazepam is combined with Lidocaine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Lidocaine.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lidocaine.
Nordazepam
The risk or severity of adverse effects can be increased when Lidocaine is combined with Nordazepam.
Norflurane
The risk or severity of adverse effects can be increased when Lidocaine is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Lidocaine is combined with Normethadone.
Nortriptyline
The metabolism of Nortriptyline can be decreased when combined with Lidocaine.
Olanzapine
The metabolism of Olanzapine can be decreased when combined with Lidocaine.
Olaparib
The metabolism of Lidocaine can be decreased when combined with Olaparib.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Lidocaine.
Omeprazole
The metabolism of Omeprazole can be decreased when combined with Lidocaine.
Ondansetron
The metabolism of Ondansetron can be decreased when combined with Lidocaine.
Opium
The risk or severity of adverse effects can be increased when Lidocaine is combined with Opium.
Orphenadrine
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osimertinib
The serum concentration of Lidocaine can be increased when it is combined with Osimertinib.
Oxaliplatin
The metabolism of Oxaliplatin can be decreased when combined with Lidocaine.
Oxazepam
The risk or severity of adverse effects can be increased when Oxazepam is combined with Lidocaine.
Oxprenolol
The serum concentration of Lidocaine can be increased when it is combined with Oxprenolol.
Oxtriphylline
The metabolism of Oxtriphylline can be decreased when combined with Lidocaine.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Lidocaine.
Oxymorphone
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Lidocaine.
Palbociclib
The serum concentration of Lidocaine can be increased when it is combined with Palbociclib.
Paliperidone
The risk or severity of adverse effects can be increased when Paliperidone is combined with Lidocaine.
Palonosetron
The metabolism of Palonosetron can be decreased when combined with Lidocaine.
Panobinostat
The serum concentration of Lidocaine can be increased when it is combined with Panobinostat.
Pantoprazole
The metabolism of Pantoprazole can be decreased when combined with Lidocaine.
Paraldehyde
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Lidocaine.
Paroxetine
The metabolism of Lidocaine can be decreased when combined with Paroxetine.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Lidocaine.
Peginterferon Alfa-2b
The serum concentration of Lidocaine can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol
The serum concentration of Lidocaine can be increased when it is combined with Penbutolol.
Pentamidine
The metabolism of Pentamidine can be decreased when combined with Lidocaine.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Lidocaine.
Pentobarbital
The metabolism of Lidocaine can be increased when combined with Pentobarbital.
Pentoxifylline
The metabolism of Pentoxifylline can be decreased when combined with Lidocaine.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
Perazine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Perazine.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Lidocaine.
Perphenazine
The metabolism of Perphenazine can be decreased when combined with Lidocaine.
Phenacetin
The metabolism of Phenacetin can be decreased when combined with Lidocaine.
Phenobarbital
The metabolism of Lidocaine can be increased when combined with Phenobarbital.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Lidocaine is combined with Phenoxyethanol.
Phenytoin
The metabolism of Lidocaine can be increased when combined with Phenytoin.
Pimozide
The metabolism of Pimozide can be decreased when combined with Lidocaine.
Pindolol
The serum concentration of Lidocaine can be increased when it is combined with Pindolol.
Pioglitazone
The metabolism of Lidocaine can be decreased when combined with Pioglitazone.
Pipamperone
The risk or severity of adverse effects can be increased when Lidocaine is combined with Pipamperone.
Pipothiazine
The metabolism of Pipotiazine can be decreased when combined with Lidocaine.
Pirfenidone
The serum concentration of Pirfenidone can be increased when it is combined with Lidocaine.
Pirinitramide
The risk or severity of adverse effects can be increased when Lidocaine is combined with Piritramide.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Lidocaine.
Pizotyline
The risk or severity of adverse effects can be increased when Pizotifen is combined with Lidocaine.
Pomalidomide
The metabolism of Pomalidomide can be decreased when combined with Lidocaine.
Posaconazole
The metabolism of Lidocaine can be decreased when combined with Posaconazole.
Practolol
The serum concentration of Lidocaine can be increased when it is combined with Practolol.
Pramipexole
Lidocaine may increase the sedative activities of Pramipexole.
Pramoxine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Pramocaine.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Lidocaine.
Prazepam
The risk or severity of adverse effects can be increased when Lidocaine is combined with Prazepam.
Praziquantel
The metabolism of Praziquantel can be decreased when combined with Lidocaine.
Pregabalin
The therapeutic efficacy of Lidocaine can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Prilocaine.
Primaquine
The metabolism of Primaquine can be decreased when combined with Lidocaine.
Primidone
The metabolism of Lidocaine can be increased when combined with Primidone.
Procaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Procaine.
Prochlorperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lidocaine.
Progesterone
The metabolism of Progesterone can be decreased when combined with Lidocaine.
Proguanil
The metabolism of Proguanil can be decreased when combined with Lidocaine.
Promazine
The metabolism of Promazine can be decreased when combined with Lidocaine.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Lidocaine.
Propafenone
The serum concentration of Lidocaine can be increased when it is combined with Propafenone.
Proparacaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Proparacaine.
Propofol
The metabolism of Propofol can be decreased when combined with Lidocaine.
Propoxyphene
The risk or severity of adverse effects can be increased when Lidocaine is combined with Dextropropoxyphene.
Propranolol
The serum concentration of Lidocaine can be increased when it is combined with Propranolol.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Lidocaine.
Pyrazinamide
The metabolism of Pyrazinamide can be decreased when combined with Lidocaine.
Pyrimethamine
The metabolism of Lidocaine can be decreased when combined with Pyrimethamine.
Quazepam
The serum concentration of Lidocaine can be increased when it is combined with Quazepam.
Quetiapine
The risk or severity of adverse effects can be increased when Quetiapine is combined with Lidocaine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Quetiapine is combined with Lidocaine.
Quinidine
The metabolism of Lidocaine can be decreased when combined with Quinidine.
Quinine
The metabolism of Quinine can be decreased when combined with Lidocaine.
Rabeprazole
The metabolism of Lidocaine can be decreased when combined with Rabeprazole.
Ramelteon
The metabolism of Ramelteon can be decreased when combined with Lidocaine.
Ranitidine
The metabolism of Ranitidine can be decreased when combined with Lidocaine.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Lidocaine.
Rasagiline
The metabolism of Rasagiline can be decreased when combined with Lidocaine.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Lidocaine.
Remoxipride
The risk or severity of adverse effects can be increased when Lidocaine is combined with Remoxipride.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Lidocaine.
Resveratrol
The metabolism of Resveratrol can be decreased when combined with Lidocaine.
Rifabutin
The metabolism of Lidocaine can be increased when combined with Rifabutin.
Rifampin
The metabolism of Lidocaine can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Lidocaine can be increased when combined with Rifapentine.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Lidocaine.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Lidocaine.
Riluzole
The metabolism of Riluzole can be decreased when combined with Lidocaine.
Risperidone
The risk or severity of adverse effects can be increased when Risperidone is combined with Lidocaine.
Ritonavir
The metabolism of Lidocaine can be decreased when combined with Ritonavir.
Rizatriptan
The metabolism of Rizatriptan can be decreased when combined with Lidocaine.
Rofecoxib
The metabolism of Rofecoxib can be decreased when combined with Lidocaine.
Rolapitant
The metabolism of Lidocaine can be decreased when combined with Rolapitant.
Ropinirole
Lidocaine may increase the sedative activities of Ropinirole.
Ropivacaine
The metabolism of Ropivacaine can be decreased when combined with Lidocaine.
Rosiglitazone
The metabolism of Lidocaine can be decreased when combined with Rosiglitazone.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Lidocaine.
Rotigotine
Lidocaine may increase the sedative activities of Rotigotine.
Rucaparib
The metabolism of Rucaparib can be decreased when combined with Lidocaine.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Lidocaine.
Saquinavir
Saquinavir may increase the arrhythmogenic activities of Lidocaine.
Saquinavir Mesylate
Saquinavir may increase the arrhythmogenic activities of Lidocaine.
Sarilumab
The therapeutic efficacy of Lidocaine can be decreased when used in combination with Sarilumab.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Lidocaine.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Lidocaine.
Secobarbital
The metabolism of Lidocaine can be increased when combined with Secobarbital.
Selegiline
The metabolism of Selegiline can be decreased when combined with Lidocaine.
Sertindole
The risk or severity of adverse effects can be increased when Lidocaine is combined with Sertindole.
Sertraline
The metabolism of Sertraline can be decreased when combined with Lidocaine.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Lidocaine.
Sildenafil
The metabolism of Lidocaine can be decreased when combined with Sildenafil.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Lidocaine.
Siltuximab
The serum concentration of Lidocaine can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Lidocaine can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Lidocaine.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
Sorafenib
The metabolism of Lidocaine can be decreased when combined with Sorafenib.
Sotalol
The serum concentration of Lidocaine can be increased when it is combined with Sotalol.
ST. JOHN'S WORT EXTRACT
The serum concentration of Lidocaine can be decreased when it is combined with St. John's Wort.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Lidocaine.
Sulfadiazine
The metabolism of Lidocaine can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Lidocaine can be decreased when combined with Sulfamethoxazole.
Sulfisoxazole
The metabolism of Lidocaine can be decreased when combined with Sulfisoxazole.
Sulpiride
The risk or severity of adverse effects can be increased when Lidocaine is combined with Sulpiride.
Suvorexant
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tacrine
The metabolism of Tacrine can be decreased when combined with Lidocaine.
Talinolol
The serum concentration of Lidocaine can be increased when it is combined with Talinolol.
Tamoxifen
The metabolism of Tamoxifen can be decreased when combined with Lidocaine.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
Tasimelteon
The risk or severity of adverse effects can be increased when Tasimelteon is combined with Lidocaine.
technetium Tc 99m tilmanocept
Lidocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
Telaprevir
The risk or severity of adverse effects can be increased when Telaprevir is combined with Lidocaine.
Telithromycin
The metabolism of Lidocaine can be decreased when combined with Telithromycin.
Temafloxacin
The metabolism of Temafloxacin can be decreased when combined with Lidocaine.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Lidocaine.
Tenofovir Disoproxil
The metabolism of Lidocaine can be decreased when combined with Tenofovir disoproxil.
Terbinafine
The metabolism of Lidocaine can be decreased when combined with Terbinafine.
Terbutaline
The serum concentration of Lidocaine can be increased when it is combined with Terbutaline.
Terbutaline Sulfate
The serum concentration of Lidocaine can be increased when it is combined with Terbutaline.
Teriflunomide
The serum concentration of Lidocaine can be decreased when it is combined with Teriflunomide.
Tertatolol
The serum concentration of Lidocaine can be increased when it is combined with Tertatolol.
Tetrabenazine
The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lidocaine.
Tetracaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Lidocaine is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.
Thalidomide
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Theobromine
The metabolism of Theobromine can be decreased when combined with Lidocaine.
Theophylline
The metabolism of Lidocaine can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Lidocaine can be decreased when combined with Theophylline.
Thiabendazole
The metabolism of Thiabendazole can be decreased when combined with Lidocaine.
Thiamylal
The risk or severity of adverse effects can be increased when Lidocaine is combined with Thiamylal.
Thiopental
The risk or severity of adverse effects can be increased when Lidocaine is combined with Thiopental.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Lidocaine is combined with Thiopental.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Lidocaine.
Thiotepa
The metabolism of Lidocaine can be decreased when combined with Thiotepa.
Thiothixene
The metabolism of Thiothixene can be decreased when combined with Lidocaine.
Tiagabine
The risk or severity of adverse effects can be increased when Tiagabine is combined with Lidocaine.
Tiapride
The risk or severity of adverse effects can be increased when Lidocaine is combined with Tiapride.
Ticagrelor
The metabolism of Lidocaine can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Lidocaine can be decreased when combined with Ticlopidine.
Timolol
The serum concentration of Lidocaine can be increased when it is combined with Timolol.
Timolol Anhydrous
The serum concentration of Lidocaine can be increased when it is combined with Timolol.
Tipranavir
The metabolism of Lidocaine can be decreased when combined with Tipranavir.
Tizanidine
The serum concentration of Tizanidine can be increased when it is combined with Lidocaine.
Tocilizumab
The serum concentration of Lidocaine can be decreased when it is combined with Tocilizumab.
Tolbutamide
The metabolism of Lidocaine can be decreased when combined with Tolbutamide.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Lidocaine.
Tolperisone
The metabolism of Tolperisone can be decreased when combined with Lidocaine.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Lidocaine.
Topiramate
The risk or severity of adverse effects can be increased when Topiramate is combined with Lidocaine.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Lidocaine.
Toremifene
The metabolism of Toremifene can be decreased when combined with Lidocaine.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Lidocaine.
Tranylcypromine
The metabolism of Lidocaine can be decreased when combined with Tranylcypromine.
Trazodone
The risk or severity of adverse effects can be increased when Lidocaine is combined with Trazodone.
Triamterene
The metabolism of Triamterene can be decreased when combined with Lidocaine.
Triazolam
The risk or severity of adverse effects can be increased when Triazolam is combined with Lidocaine.
Triazulenone
The risk or severity of adverse effects can be increased when Lidocaine is combined with Loprazolam.
Trifluoperazine
The metabolism of Trifluoperazine can be decreased when combined with Lidocaine.
Triflupromazine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Triflupromazine.
Trimethoprim
The metabolism of Lidocaine can be decreased when combined with Trimethoprim.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Lidocaine.
Triprolidine
The risk or severity of adverse effects can be increased when Triprolidine is combined with Lidocaine.
Ulipristal
The metabolism of Ulipristal can be decreased when combined with Lidocaine.
Urethane
The risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl carbamate.
Valproate
The risk or severity of adverse effects can be increased when Lidocaine is combined with Valproic Acid.
Valproic Acid
The risk or severity of adverse effects can be increased when Lidocaine is combined with Valproic Acid.
Valsartan
The metabolism of Lidocaine can be decreased when combined with Valsartan.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lidocaine.
Venlafaxine
The metabolism of Lidocaine can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Lidocaine can be decreased when combined with Verapamil.
Vigabatrin
The risk or severity of adverse effects can be increased when Vigabatrin is combined with Lidocaine.
Vincristine
The excretion of Vincristine can be decreased when combined with Lidocaine.
Vitamin K 3
The metabolism of Menadione can be decreased when combined with Lidocaine.
Voriconazole
The metabolism of Lidocaine can be decreased when combined with Voriconazole.
Vortioxetine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Vortioxetine.
Voxilaprevir
The metabolism of Voxilaprevir can be decreased when combined with Lidocaine.
Warfarin
The metabolism of Warfarin can be decreased when combined with Lidocaine.
Xylazine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Xylazine.
Zafirlukast
The metabolism of Lidocaine can be decreased when combined with Zafirlukast.
Zaleplon
The risk or severity of adverse effects can be increased when Zaleplon is combined with Lidocaine.
Ziconotide
The risk or severity of adverse effects can be increased when Ziconotide is combined with Lidocaine.
Zileuton
The metabolism of Zileuton can be decreased when combined with Lidocaine.
Ziprasidone
The metabolism of Lidocaine can be decreased when combined with Ziprasidone.
Zolmitriptan
The metabolism of Zolmitriptan can be decreased when combined with Lidocaine.
Zolpidem
Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide
The risk or severity of adverse effects can be increased when Zonisamide is combined with Lidocaine.
Zopiclone
The risk or severity of adverse effects can be increased when Zopiclone is combined with Lidocaine.
Zotepine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Zotepine.
Zuclopenthixol
The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lidocaine.
